BioNTech Shutters Pandemic-Era Plants as Founders Map a Separate Future

BioNTech is closing German and Singapore sites after failing to find buyers, as its founders set up a separate Mainz pharma venture.

BioNTech is dismantling the industrial footprint it built during the vaccine boom, closing sites in Germany and Singapore after failing to find buyers for the facilities, Reuters reported. The move, confirmed as the company pivots away from pandemic-related manufacturing, marks the definitive end of its interim arrangements and forces management to right-size fixed costs against a very different revenue reality.

Investors absorbed the news without much enthusiasm. The stock changed hands at EUR 86.10 on the day, a decline of 0.5% from the previous close, though it has still managed a gain of 7.0% since the start of the year. The shares were trading at EUR 87.00 in separate dealings, reflecting a muted response to the cleanup of the site network.

The capacity overhang from the Covid era tied up resources that are now needed for the clinical pipeline. Management's task is to convince the capital markets that scaling back industrial infrastructure signals discipline rather than weakness — a redirection of spending toward cancer medicines.

A Successor Company Takes Shape in Mainz

Complicating the narrative, BioNTech's two co-founders have set up a separate pharmaceutical venture. U?ur ?ahin and Özlem Türeci founded Arife in Mainz on September 1, an entity organizationally distinct from BioNTech. The new company will pursue research, manufacturing and distribution of pharmaceutical products, including next-generation mRNA drugs. Media reports on Friday indicated the founders reaffirmed their intention to leave BioNTech by the end of 2026.

?ahin has also been trimming his direct holdings. A mandatory disclosure filed Thursday showed the CEO sold 30,000 ordinary shares on Wednesday and a further 39,000 on Thursday, all executed under a trading plan established on June 3 in compliance with US Rule 10b5-1. While such transactions are routine under long-term arrangements, sales from the top ranks during an operational overhaul can give investors pause.

Clinical Data Carries the Valuation

With pandemic revenue fading, the investment case now rests almost entirely on late-stage trial success rates. Seasonal vaccine approvals continue — Health Canada cleared a Comirnaty shot adapted to the XFG variant for people aged six months and older for the 2026/2027 season on September 17 — but these provide steady cash flow rather than a growth engine.

The real lever sits in oncology. Roughly two weeks ago, BioNTech and partner OncoC4 released updated Phase 3 data from the PRESERVE-003 study of Gotistobart in previously treated squamous non-small cell lung cancer. The first-stage analysis showed a median overall survival of 18.5 months for the drug candidate versus 10.0 months on standard docetaxel chemotherapy. Both companies classified the data as not registration-relevant, and the confirmatory second stage of the trial is ongoing.

That doubling of the survival benefit has fed market confidence that BioNTech has the technological foundation to become a serious oncology player. Should subsequent datasets confirm the results, the market could assign a substantially higher valuation premium to the cancer portfolio.

Risks Cut Both Ways

Against the bullish case stand concrete hazards. Late-stage cancer drug development carries steep failure rates and high clinical hurdles. Setbacks in registration-relevant studies would undermine the company's entire strategic story and raise questions about whether heavy research spending will ever generate matching returns.

Operational mishaps add to the caution. On September 15, a fire broke out in the exhaust system of a laboratory building at the Mainz site, prompting three employees to be taken to hospital as a precaution.

On the organizational front, the supervisory board has approved KPMG AG Wirtschaftsprüfungsgesellschaft as auditor for fiscal year 2027, subject to formal shareholder approval at the upcoming annual general meeting.

The Chart Level to Watch

Technically, the picture holds as long as the stock stays above its 50-day moving average of EUR 85.21. A decisive break below that support would open the door to a retest of the year's lower trading ranges. The ultimate driver, however, remains clinical research — the results that will determine whether BioNTech completes its transition into a leading oncology company.